checkAd

     101  0 Kommentare AtriCure to Participate at the Oppenheimer 31st Annual Healthcare Conference

    AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in surgical treatments for atrial fibrillation (Afib) and left atrial appendage (LAA) management, today announced that the company will be participating in the upcoming Oppenheimer 31st Annual Healthcare Conference.

    AtriCure’s management is scheduled to present on Tuesday, March 16, 2021, at 1:10 p.m. Eastern Time. Interested parties may access a live and archived audio webcast of the presentation by visiting the “Investors” section of the company’s website at https://ir.atricure.com.

    About AtriCure

    AtriCure, Inc. provides innovative technologies for the treatment of Afib and related conditions. Afib affects more than 33 million people worldwide. Electrophysiologists and cardiothoracic surgeons around the globe use AtriCure technologies for the treatment of Afib and reduction of Afib related complications. AtriCure’s Isolator Synergy Ablation System is the first and only medical device to receive FDA approval for the treatment of persistent Afib. AtriCure’s AtriClip Left Atrial Appendage Exclusion System products are the most widely sold LAA management devices worldwide. For more information, visit AtriCure.com or follow us on Twitter @AtriCure.



    Business Wire (engl.)
    0 Follower
    Autor folgen

    AtriCure to Participate at the Oppenheimer 31st Annual Healthcare Conference AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in surgical treatments for atrial fibrillation (Afib) and left atrial appendage (LAA) management, today announced that the company will be participating in the upcoming Oppenheimer 31st Annual …